Biomimetic synthesis, biosynthetic pathway engineering and structure activities studies of unique glycosolyated macrolactams
Biomimetic synthesis, biosynthetic pathway engineering and structure activities studies of unique glycosolyated macrolactams
批准号:
391056593
负责人:
Professorin Dr. Christine Beemelmanns
金额:
$0.0万
依托单位国家:
德国
项目类别:
Research Grants
财政年份:
2017
资助国家:
德国
项目状态:
已结题
起止时间:
2016-12-31 至 2021-12-31
中文摘要
对微生物共生体的化学分析有助于更深入地了解共生系统的演化,同时也为获得具有内在生物活性的天然产品提供了途径。直到现在,人们才意识到这些天然产品对发现具有潜在应用于人类健康的新型抗生素的影响。然而,由于抗生素的使用不可避免地会选择耐药病原体,因此需要新的抗生素来源。在耐甲氧西林金黄色葡萄球菌(MRSA)和耐万古霉素肠球菌(VRE)等多重耐药菌株的时代,对新类别抗生素的需求和新靶点的发现都很高。广泛地说,该项目旨在阐明真菌白蚁的细菌共生体Amycolatopsis M39的化学成分。这种方法的吸引人的特点和目标包括:(1)对化学研究较少的共生菌和它们各自的次生代谢物进行基因组驱动的分析;(2)现代半合成和全合成,以评估具有药理意义的靶标结构和生物合成中间体的绝对结构;以及(3)生成具有内在生物活性的次生代谢物的底物库。我们打算利用有机合成、DNA测序和基因组挖掘方法以及合成生物学方面的最新进展。我们的目标是将天然产品与其基因组基础联系起来,以了解其生物合成的基础,并将利用生成的信息建立一个更多属的发现和评估平台。该项目受益于与其他在化学生态学和生物合成方面拥有强大专业知识的学术合作伙伴的合作,以及内部药理学和临床前评估平台的存在。这项建议的关键要素是各学科之间的协同作用,因为合作研究联合体在天然产品化学、化学分析和有机合成化学领域提供了广泛的专业知识,这对于解决所概述的雄心勃勃的任务是必要的。本项目将解决以下三个具体目标:(1)我们将采用高效和模块化的策略来确定大霉素A的绝对结构及其核心结构,该策略同时为生物合成途径的研究提供硫酸酯前体。在结构上简化的大霉素将被(生物)合成,以进行结构-活性研究。(2)我们的目标是利用一个异源表达系统来理解并随后操纵大霉素的生物合成途径,该系统可以转移到M39中其他尚未完全表征的基因簇的分析中,以充分挖掘化学潜力。(3)我们的目标是阐明其他编码的生物合成基因簇的诱导方式,并鉴定各自的次生代谢物。
英文摘要
The chemical analysis of microbial symbionts yields a deeper understanding of the evolution of symbiotic systems, and at the same time grants access to intrinsically bioactive natural products. It is only now that the impact of these natural products on the discovery of novel antibiotics with potential applications for human health is being realized. Yet, novel sources of antibiotics are needed since the use of antibiotics inevitably selects for resistant pathogens. In times of multiresistant strains such as methicillin resistant Staphylococcus aureus (MRSA) and vancomycin resistant Enterococci (VRE), the demand for new classes of antibiotics and the discovery of new targets, is high. Broadly, the project aims to elucidate the chemical repertoire of a bacterial symbiont, Amycolatopsis M39, of fungus-growing termites. Attractive features and goals of this approach include: (1) the genome-driven analysis of chemically poorly studied symbiotic bacteria and their respective secondary metabolites; (2) modern semi and total synthesis to evaluate the absolute structure of pharmacologically interesting target structures and biosynthetic intermediates; and (3) the generation of a substrate library of intrinsically bioactive secondary metabolites. We intend to capitalize on recent advances in organic synthesis, DNA sequencing and genome mining approaches, as well as synthetic biology. We aim to link natural products to their genomic basis to understand the underpinnings of their biosynthesis, and we will use the generated information to build up a more genera discovery and evaluation platform.This project benefits from collaborations with other academic partners having strong expertise in chemical ecology and biosynthesis, and the presence of an in-house pharmacological and pre-clinical evaluation platform. Key element of this proposal is the synergistic interaction between the disciplines as the collaborative research consortium offers a broad range of expertise in the fields of natural product chemistry, chemical analytics and organic synthetic chemistry, which is necessary to tackle the outlined ambitious tasks. The following three specific aims will be addressed within this project: (1) We will determine the absolute structure of macrotermycin A and its core structure by using an efficient and modular strategy, a strategy which provides at the same time thioester precursors for biosynthetic pathway studies. Structurally simplified macrotermycins will be (bio)synthesized to enable structure-activity studies. (2) We aim to understand and subsequently manipulate the putative biosynthetic pathway of macrotermycins using a heterologous expression system that can be transferred to the analysis of other not yet fully characterized gene clusters within M39 to fully harvest the chemical potential. (3) We aim to elucidate the means by which other encoded biosynthetic gene clusters are induced and identify the respective secondary metabolites.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Exploitation and total synthesis of new microbial sphingolipid-type signaling molecules (EXSPHINGO)
-
批准号:288869487
-
项目类别:Research Grants
-
资助金额:$0.0万
-
财政年份:2016
-
负责人:Professorin Dr. Christine Beemelmanns
-
依托单位:
OMICs based analysis of cytochalasans in fungal-bacteria-insect interactions
-
批准号:455064904
-
项目类别:Research Units
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Professorin Dr. Christine Beemelmanns
-
依托单位:
国内基金
海外基金
登录
查看更多内容
胆固醇合成蛋白CYP51介导线粒体通透性转换诱发Th17/Treg细胞稳态失衡在舍格伦综合征中的作用机制研究
-
批准号:82370976
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:郑凌艳
-
依托单位:
“肠—肝轴”PPARα/CYP8B1胆汁酸合成信号通路在减重手术改善糖脂代谢中的作用与机制
-
批准号:82370902
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:田景琰
-
依托单位:
lncGEI诱导湖羊卵巢颗粒细胞E2合成的分子机制
-
批准号:32372856
-
项目类别:面上项目
-
资助金额:50.00万元
-
批准年份:2023
-
负责人:李隐侠
-
依托单位:
脂肪酸合成通过GDF15/IRS2介导胰岛素抵抗促进血管内皮细胞活化导致脓毒症肺损伤的机制研究
-
批准号:82372203
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:李然然
-
依托单位:
环状RNA circ-PRKAA1调控肝癌细胞脂代谢重编程的研究
-
批准号:32000527
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:李启东
-
依托单位:
ALDH6A1缺损重塑糖脂代谢促进肝细胞癌发生的机制研究
-
批准号:91957109
-
项目类别:重大研究计划
-
资助金额:79.0万元
-
批准年份:2019
-
负责人:黄赞
-
依托单位:
新型滤波器综合技术-直接综合技术(Direct synthesis Technique)的研究及应用
-
批准号:61671111
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:肖飞
-
依托单位:
双硅化合物反应及天然产物合成应用研究
-
批准号:21172150
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2011
-
负责人:宋振雷
-
依托单位:
新型M4受体选择性拮抗剂的研究
-
批准号:30973615
-
项目类别:面上项目
-
资助金额:32.0万元
-
批准年份:2009
-
负责人:何新华
-
依托单位:
基于penicillide结构的类天然产物合成及其胆固醇酯转运蛋白抑制的研究
-
批准号:20872019
-
项目类别:面上项目
-
资助金额:32.0万元
-
批准年份:2008
-
负责人:雷新胜
-
依托单位: